ISSN: 1859 - 2872
Evaluation of the results of cetuximab combined radiotherapy in the radical treatment of head and neck squamous cell carcinoma stage III-IVB
Main Article Content
Abstract
Objective: To evaluate the effectiveness of radiation + cetuximab regimen: response rate, overall survival, progression-free survival. Subject and method: Patients with stage III to IVB H&N SCC received cetuximab combined radiotherapy from 2016 to 2022 at Military Hospital 175 with appropriate inclusion and exclusion criteria. Descriptive, retrospective study. Result: 74 patients were recruited with the following characteristics: mean age 68.4 ± 15.1; 93.2% were male; 91.9% had co-morbidities; 85.1% had PS1; tumor position in the oral cavity 17.6%, oropharynx 32.4%, hypopharynx 17.6%, larynx 24.3%, nasal cavity 8.1%; stage IV 70.2%; BED radiation dose was mainly 70Gy (86.5%); 3D (46.0%), IMRT (54.0%); compliance rate with cetuximab 91.9%; toxicity grade 3 or more including dermatitis 37.8%, mucositis 58.1%, skin rash 12.1%. Average follow-up time 45.4 months, response to treatment CR (57.0%), PR (22.0%), SD (21.0%); median PFS 30.0 months (95% CI: 6.0 - 60.0), median OS 48.0 months (95% CI: 12.2 - 68.3). Conclusion: Radiotherapy + cetuximab regimen is highly effective, well tolerated, and can be applied in the treatment of head and neck squamous cell carcinoma, stage III-IVB inoperation patients, especially in the elderly and co-morbidity diseased group.
Article Details
References
2. Lâm Đức Hoàng và cộng sự (2022) Đánh giá hiệu quả điều trị ung thư đầu cổ loại tế bào vảy bằng xạ trị ngoài kết hợp thuốc nhắm trúng đích. Tạp chí Y học Việt Nam, tập 519, tháng 10- số chuyên đề -2022, tr .31- 40.
3. Nguyễn Thị Thái Hòa (2015) Đánh giá kết quả điều trị kết hợp kháng thể đơn dòng Nimotuzumab-Hóa xạ trị ung thư biểu mô vảy vùng đầu cổ giai đoạn lan tràn tại vùng đầu cổ. Luận án tiến sĩ y học, Đại học Y Hà Nội.
4. Blanchard P, Landais C, Petit C, Zhang Q, Grégoire V, Tobias J et al (2016) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 100 randomized trials and 19,248 patients, on behalf of MACH-NC Group. Ann Oncol. 27(Suppl 6): 950.
5. Bonner J A, Harari P M, Giralt J, Azarnia N et al (2006) Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine 354 (6): 567-578.
6. Bonner JA, Harari PM, Giralt J, Cohen RB et al, (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. The Lancet Oncology, 11 (1): 21-28.
7. Keam B, Machiels J P, Kim H R, Licitra L et al (2021) Pan-Asian adaptation of the EHNS– ESMO– ESTRO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with squamous cell carcinoma of the head and neck. ESMO Open, 6 (6).
8. NCCN Clinical Practice Guidelines in Oncology. Head and Neck Cancers V1. (2023). Available online at: http://www.nccn.org/professionals/physician_ gls/pdf/head-and-neck.pdf (accessed Jan 30, 2023).
9. Patil V M, Noronha V, Menon N S, Laskar S et al (2022) Results of phase 3 randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation. Journal of Clinical Oncology, 40 (17_suppl), pp. LBA6003-LBA6003.
10. Porceddu S V, Scotté F, Aapro M, Salmio S et al (2020) Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy. Frontiers in Oncology, 9 pp.
11. Sung H, Ferlay J, Siegel R L, Laversanne M, et al, (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71 (3): 209-249.
Article Sidebar
